Lupin to attend Kotak, J.P. Morgan investor meets in September
- Lupin will attend the Kotak Healthcare Conference on September 17, 2026
- The company is also scheduled for a group meet at the J.P. Morgan India Conference on September 21
- Both events are in-person group meetings with analysts and institutional investors
- Presentations will follow content already available on exchange websites

*this image is generated using AI for illustrative purposes only.
Lupin will participate in two analyst and investor meetings in September 2026, engaging with the investment community at major financial conferences.
The company disclosed the schedule pursuant to Regulation 30 of the SEBI Listing Regulations, confirming its participation in group meets held in person.
Meeting details
Lupin will engage with analysts and institutional investors at the following events:
| Date | Event | Mode | Nature |
|---|---|---|---|
| September 17, 2026 | Kotak Healthcare Conference | In person | Group meet |
| September 21, 2026 | J.P. Morgan India Conference | In person | Group meet |
The company noted that the schedule is subject to change due to exigencies by the company or event organizers. Any presentations made during these events will align with those already available on the company’s website and stock exchanges.
Regulatory disclosure
The disclosure was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited. The registered office of the company is located in Mumbai.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.01% | -3.82% | -10.95% | -10.20% | +8.27% | +112.68% |
What specific strategic updates or financial guidance is Lupin likely to present at the Kotak Healthcare and J.P. Morgan conferences?
How might investor sentiment regarding Lupin's generic drug portfolio shift following these September 2026 engagements?
Are there any pending regulatory approvals or product launches that Lupin may highlight to address current market concerns during these meetings?


































